Anika Therapeutics announced the first U.S. commercial sale of Monovisc by its commercial partner — DePuy Synthes Mitek Sports Medicine.
Monovisc received marketing approval from the U.S. Food and Drug Administration in February. It is indicated for the treatment of pain in osteoarthritis of the knee for patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics.
Anika Therapeutics develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. DePuy Synthes Mitek Sports Medicine is a provider of products for tissue protection, healing and repair, based on hyaluronic acid technology.
More Articles on Devices:
Mazor Robotics 2013 Net Loss Shoots to $20M
Advancement in Lateral Spine Technology: Q&A with Vertebral Technologies, Inc. CEO Dr. Jeffrey Felt
EDGE Orthopaedics Receives FDA 510(k) Clearance for BITE Compression Screws